background: considering the increasing number of patients with hemophilia and infrastructure requirements for a comprehensive approach, development of a recombinant factor has become a milestone. the objective of this study was to assess the safety, efficacy and non inferiority of safacto (recombinant factor viii) compared with plasma-derived factor in the treatment of hemophilia a. methods: 10 ...

Background: Considering the increasing number of patients with hemophilia and infrastructure requirements for a comprehensive approach, development of a recombinant factor has become a milestone. The objective of this study was to assess the safety, efficacy and non inferiority of Safacto (Recombinant factor VIII) compared with plasma-derived factor in the treatment of hemophilia A. Methods: 10 ...

Background: Plasma medicine is an innovative and emerging field used in a broad range of medical conditions. Objective: The present study focused on consumption, documentation pattern and traceability of plasma-derived medicines in a teaching and referral hospital. Method: A two-step study was conducted from October to December 2015. During the first phase, the patient records receiving plasm...

Background: Plasma medicine is an innovative and emerging field used in a broad range of medical conditions. Objective: The present study focused on consumption, documentation pattern and traceability of plasma-derived medicines in a teaching and referral hospital. Method: A two-step study was conducted from October to December 2015. During the first phase, the patient records receiving plasm...

Context:  The major motivation for the preparation of the plasma derived biological medicine was the treatment of casualties from the Second World War.  Due to the high expenses for preparation of plasma derived products, achievement of self-sufficiency in human plasma biotechnological industry is an important goal for developing countries.Evidence Acquisition:  The complexity of the bloo...

A recombinant Factor VIII (Factor VIII-delta II) consists of a unique polypeptide chain of 165 kDa deleted from the major part of the B-domain and from the cleavage site at Arg-1648-Glu-1649 found in plasma-derived Factor VIII. It was expressed in mammalian cells in serum-free medium containing von Willebrand factor and purified by a one-step immunopurification. The recombinant Factor VIII was ...

The rising incidence of neutralizing antibodies (inhibitors) against therapeutic factor VIII prompted the conduct of studies to answer the question as to whether this rise is related to the introduction of recombinant factor VIII products. The present article summarizes current opinions and results of non-clinical and clinical studies on the immunogenic potential of recombinant compared to plas...

many investigations have proved relations between abo blood groups with some diseases and factor viii and von willebrand level in plasma. in this study we investigated a relation between abo blood groups and factor viii and ix inhibitors in 102 patients with haemophilia a and 48 patients with haemophilia b. the assay of inhibitor was done by bethesda method. there were no relation between abo b...

Thrombocytopenic serum is a simple reagent derived from platelet-poor plasma. The high levels of factor V and ;zero' levels of factor VIII in this reagent make it a reliable alternative to haemophilia A plasma in the qualitative and quantitative assessment of factor VIII in the thromboplastin generation test.

Protein specific aptamers are highly applicable affinity ligands in different fields of research and clinical applications. They have been developed against various targets, in particular, bio-macromolecules such as proteins. Among human proteins, the coagulation factors are the most attractive targets for aptamer selection and their specific aptamers had valuable characteristics in therapeutic...